Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Iveric Bio Inc (NQ: ISEE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iveric Bio Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
IVERIC bio Inc. (NASDAQ: ISEE) Records 52-Week High Thursday Morning
Via Investor Brand Network
IVERIC bio Inc. (NASDAQ: ISEE) Making Surprising Moves in Monday Session
Via Investor Brand Network
The Latest Analyst Ratings for IVERIC bio
Via Benzinga
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
From Kahn Swick & Foti, LLC
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
By David Willey, Benzinga 
Via TheNewswire.com
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? 
Via News Direct
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)
From Brodsky & Smith LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. 
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
Via Benzinga
ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
From IVERIC Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.